La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Nevro a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Nevro..

Nevro (NYSE:NVRO) Azioni, Catena delle Opzioni

Nevro

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Nevro Corp

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 61.6% to $0.21 during Tuesday's pre-market session. The company's market cap stands at $2.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 46.12% to $0.29. The market value of their outstanding shares is at $43.0 million. </li>
<li>Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares increased by 28.75% to $6.85. The market value of their outstanding shares is at $255.3 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) shares rose 28.17% to $15.97. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares rose 27.56% to $2.08. The company's market cap stands at $426.1 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares moved upwards by 22.6% to $3.2. The market value of their outstanding shares is at $51.8 million. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock decreased by 40.2% to $1.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $166.8 million. As per the press release, Q3 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock decreased by 31.36% to $49.1. The company's market cap stands at $728.0 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 27.28% to $0.8. The market value of their outstanding shares is at $24.2 million. The company's, Q3 earnings came out today. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares decreased by 25.81% to $3.45. The market value of their outstanding shares is at $107.0 million. The company's, Q3 earnings came out today. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) stock fell 25.3% to $16.27. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares declined by 18.4% to $0.82. The market value of their outstanding shares is at $116.1 million. As per the press release, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CCLD

CCLDP

CERO

HRTX

LGMK

NGNE

NVRO

RMTI

SNDX

STIM

TSHA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Medical device company Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) stock is trading higher on Tuesday after it announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord <a href="https://www.benzinga.com/pressreleases/24/11/n41896477/nevros-hfx-iq-spinal-cord-stimulation-with-ai-technology-receives-ce-mark-certification-in-europe-" target="_blank" rel="noreferrer noopener">stimulation (SCS) system</a>.
The company says HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief.
HFX iQ starts patients on the program most likely to provide pain relief, based on the HFX Algorithm, built from over 20 million data points and 80,000 implanted patients.
HFX iQ combines clinical inputs, such as pain relief and pain score, along with Quality of Life inputs, such as pain medication and activity level changes, to provide an individualized program setting for each patient.
HFX iQ can program low frequency and Nevro&#8217;s proprietary 10 kHz Therapy, representing the widest range of frequencies of any SCS system on the market.
The Senza HFX iQ system includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, and HFX App.
In addition to receiving CE marking, HFX iQ received FDA approval in 2022.
Nevro will offer the HFX iQ system in select European countries starting in the first quarter of 2025.
Nevro reported an EPS loss of $(0.41), beating the consensus of $(0.76). Sales were $96.91 million, surpassing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41887810/nevro-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $93.1 million</a>.
Guidance: Nevro expects 2024 revenue of $400 million-$405 million compared to the consensus of $402.6 million.
The company raised its full-year 2024 adjusted EBITDA loss guidance to $18 million-$16 million&nbsp;from its previous loss guidance of $20 million-$18 million.
Analyst Reaction:
<ul>
<li>Piper Sandler maintains Nevro with an Underweight rating, lowering the <a href="https://www.benzinga.com/quote/NVRO/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $7 to $6</a>.</li>
<li>Baird reaffirms Nevro with a Neutral and raises the price target from $5 to $6.</li>
<li>RBC Capital reiterates Nevro with a Sector Perform and maintains a price target of $7.</li>
</ul>
Price Action: NVRO stock is up 8.46% at $5.77 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41907137/astrazeneca-lifts-2024-forecast-on-better-than-expected-q3-performance-says-it-takes-china-investigations-very-seriously" target="_blank" rel="noreferrer noopener">AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations &#8216;Very Seriously&#8217;</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

News

Health Care

Why Medical Device Firm Nevro Stock Is Trading Higher On Tuesday

Canaccord Genuity analyst William Plovanic maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Hold and lowers the price target from $8 to $7.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Nevro, Lowers Price Target to $7

In the last three months, 4 analysts have published ratings on Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.25, a high estimate of $7.00, and a low estimate of $6.00. A decline of 3.4% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1731427222_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nevro. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$6.89</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nevro. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nevro compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nevro's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nevro's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nevro analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Nevro Better</h2>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Nevro: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Nevro's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -4.27%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -18.79%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nevro's ROE excels beyond industry benchmarks, reaching -7.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Nevro's ROA stands out, surpassing industry averages. With an impressive ROA of -3.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.88.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Nevro Through Analyst Insights

JMP Securities analyst David Turkaly reiterates Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Nevro

RBC Capital analyst Shagun Singh reiterates Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Sector Perform and maintains $7 price target.

RBC Capital Reiterates Sector Perform on Nevro, Maintains $7 Price Target

General

Nevro Corp shares are trading higher after Baird raised its price target on the stock from $5 to $6. Additioanlly, the company announced it received a CE mark certification in Europe for its HFX iQ spinal cord stimulation system.

HFX iQ is digitally enabled and designed to optimize care by collecting patient data and guiding the patient through a personalized treatment pathway. It provides several key advantages over other SCS systems, including:
<ul>
<li>Indication-specific HFX Algorithms&#x2122; for back and leg pain, non-surgical refractory back pain, painful diabetic neuropathy, chronic upper limb and neck pain.</li>
<li>Customized therapy adjustment recommendations informed by patient inputs on the HFX App.</li>
<li>The only 10 kHz Therapy&#x2122; that has CE-marked labeling for all major SCS indications and outcomes beyond pain relief.</li>
</ul>

Nevro Has Received CE Mark Certification In Europe For Its HFX iQ Spinal Cord Stimulation System

Baird analyst Mike Polark maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Neutral and raises the price target from $5 to $6.

Baird Maintains Neutral on Nevro, Raises Price Target to $6

Piper Sandler analyst Adam Maeder maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Underweight and lowers the price target from $7 to $6.

Piper Sandler Maintains Underweight on Nevro, Lowers Price Target to $6

WIIM

Nevro Corp shares are trading higher after the company reported better-than-expected Q3 financial results.

Full-Year 2024 Financial Guidance
Based on its third-quarter 2024 performance and outlook for the remainder of this year, Nevro continues to expect its full-year 2024 worldwide revenue to be in the range of approximately $400 million to $405 million. The company is raising its full-year 2024 adjusted EBITDA guidance to a range of negative $18 million to negative $16 million from its previous guidance range of negative $20 million to negative $18 million. Nevro's full-year 2024 guidance assumes that its U.S. SCS trialing growth rate in the fourth quarter of 2024 does not improve from the third quarter of 2024.

Guidance

Nevro Sees FY24 Revenue $400M-$405M Vs $402.55M Est.

Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.76) by 46.05 percent. This is a 36.92 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $96.91 million which beat the analyst consensus estimate of $93.07 million by 4.13 percent. This is a 6.69 percent decrease over sales of $103.86 million the same period last year.

Earnings

Nevro Q3 EPS $(0.41) Beats $(0.76) Estimate, Sales $96.91M Beat $93.07M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is projected to report quarterly earnings at $2.41 per share on revenue of $174.31 million. 
• Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $246.09 million. 
• Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $4.46 billion. 
• ICL Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $2.03 billion. 
• Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $110.77 million. 
• Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) is estimated to report earnings for its third quarter. 
• Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $140.07 million. 
• Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.28 per share on revenue of $2.36 million. 
• GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is estimated to report earnings for its third quarter. 
<h3>Companies Reporting After The Bell</h3>
• Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) is expected to report quarterly loss at $0.01 per share on revenue of $691.80 million. 
• Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $52.81 million. 
• Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $500.03 million. 
• Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) is estimated to report earnings for its third quarter. 
• Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) is expected to report earnings for its third quarter. 
• Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) is likely to report quarterly earnings at $1.71 per share on revenue of $8.09 billion. 
• Gatos Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) is projected to report earnings for its third quarter. 
• Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is likely to report earnings for its third quarter. 
• Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $283.55 million. 
• Ampco-Pittsburgh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AP#NYSE">AP</a>) is likely to report earnings for its third quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $30.69 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $120.80 million. 
• RMR Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMR#NASDAQ">RMR</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $220.35 million. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $28.87 million. 
• Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) is projected to report quarterly loss at $0.28 per share on revenue of $1.04 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is estimated to report quarterly earnings at $0.46 per share on revenue of $57.50 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is expected to report quarterly loss at $0.55 per share on revenue of $26.01 million. 
• QuickLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>) is likely to report quarterly loss at $0.05 per share on revenue of $4.20 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $145.89 million. 
• Assured Guaranty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $201.37 million. 
• Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $7.10 million. 
• NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $3.00 million. 
• Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is expected to report quarterly loss at $0.17 per share on revenue of $18.68 million. 
• James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $146.56 million. 
• Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $48.69 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $923.69 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $298.54 million. 
• Intevac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVAC#NASDAQ">IVAC</a>) is expected to report quarterly loss at $0.15 per share on revenue of $11.50 million. 
• Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) is likely to report quarterly loss at $0.81 per share on revenue of $93.07 million. 
• Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $248.65 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is estimated to report quarterly earnings at $0.55 per share on revenue of $85.43 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGI

ARMK

AROC

ASRT

ATER

BAER

BIOX

CCAP

GATO

GRAB

ISPR

IVAC

JRVR

LAZR

LINC

MLYS

MNDY

NPWR

NUWE

QUIK

SPNS

STRW

STXS

TALO

TISI

XAIR

YALA

ZETA

Earnings Scheduled For November 11, 2024

Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) is set to give its latest quarterly earnings report on Monday, 2024-11-11. Here's what investors need to know before the announcement.
Analysts estimate that Nevro will report an earnings per share (EPS) of $-0.81. 
Investors in Nevro are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.15 in the last quarter, leading to a 44.42% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2024/1731074556_0.png" alt="eps graph" />
<h3>Nevro Share Price Analysis</h3>
Shares of Nevro were trading at $5.34 as of November 07. Over the last 52-week period, shares are down 65.01%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Nevro</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Nevro.
Analysts have given Nevro a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $6.0, indicating a potential 12.36% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Senseonics Holdings, NeuroPace and BrainsWay, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Senseonics Holdings, with an average 1-year price target of $2.0, indicating a potential 62.55% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for NeuroPace, with an average 1-year price target of $16.5, indicating a potential 208.99% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for BrainsWay, with an average 1-year price target of $14.83, implying a potential 177.72% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary presents essential metrics for Senseonics Holdings, NeuroPace and BrainsWay, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevro</td>
<td>Neutral</td>
<td>-4.27%</td>
<td>$67.47M</td>
<td>-7.08%</td>
</tr>
<tr>
<td>Senseonics Holdings</td>
<td>Buy</td>
<td>17.91%</td>
<td>$298K</td>
<td>-207.65%</td>
</tr>
<tr>
<td>NeuroPace</td>
<td>Outperform</td>
<td>16.63%</td>
<td>$14.13M</td>
<td>-62.03%</td>
</tr>
<tr>
<td>BrainsWay</td>
<td>Buy</td>
<td>27.79%</td>
<td>$7.54M</td>
<td>1.41%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nevro ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on Equity among its peers. Overall, Nevro's performance is weaker compared to its peers in terms of financial metrics.
<h3>Unveiling the Story Behind Nevro</h3>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Financial Milestones: Nevro's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Nevro's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -4.27% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Nevro's net margin excels beyond industry benchmarks, reaching -18.79%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Nevro's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.26%, the company showcases efficient use of assets and strong financial health.
Debt Management: Nevro's debt-to-equity ratio is below the industry average at 0.88, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/NVRO/earnings">To track all earnings releases for Nevro visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Nevro's Earnings Forecast

Nevro Corp Announced The Publication Of New Data In The Journal Of Pain Research With Encouraging Results Regarding Pain Relief And Long Term Meaningful Reductions in A1C

Ratings for Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.31, along with a high estimate of $10.00 and a low estimate of $5.50. A decline of 36.05% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1727816477_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Nevro among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$6.89</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$6.89</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$5.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.20</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nevro. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nevro compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nevro's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nevro's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nevro analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Nevro's Background</h2>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Financial Milestones: Nevro's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Nevro faced challenges, resulting in a decline of approximately -4.27% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nevro's net margin is impressive, surpassing industry averages. With a net margin of -18.79%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Nevro's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -7.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Nevro's ROA stands out, surpassing industry averages. With an impressive ROA of -3.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Nevro's debt-to-equity ratio is below the industry average. With a ratio of 0.88, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Nevro: 10 Analysts Share Their Views

Citigroup analyst Joanne Wuensch maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Neutral and lowers the price target from $6.89 to $6.

Citigroup Maintains Neutral on Nevro, Lowers Price Target to $6

Nevro Launches AI-Driven HFX AdaptivAI, The First AI-Powered Spinal Cord Stimulation Technology, Following FDA Approval For Personalized Pain Relief

Citigroup analyst Joanne Wuensch upgrades Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) from Sell to Neutral and announces $6.89 price target.

Upgrades

Citigroup Upgrades Nevro to Neutral, Announces $6.89 Price Target

Piper Sandler analyst Adam Maeder assigned a Sell rating to Nevro Corp (NVRO – Research Report) today and set a price target of $6.00. The company'...

Nevro Corp (NVRO) Receives a Sell from Piper Sandler

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a price ...

RBC Capital Keeps Their Hold Rating on Nevro Corp (NVRO)

Piper Sandler analyst Adam Maeder lowered the firm's price target on Nevro (NVRO) to $6 from $7 and keeps an Underweight rating on the shares. The ...

Nevro price target lowered to $6 from $7 at Piper Sandler

Oppenheimer analyst Suraj Kalia maintained a Hold rating on Nevro Corp (NVRO – Research Report) today. The company's shares closed yesterday at $5....

Oppenheimer Sticks to Its Hold Rating for Nevro Corp (NVRO)

Nevro (NVRO) is up 28.2%, or $1.50 to $6.82. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...

Nevro rises 28.2%

Nevro Corp (NVRO) has disclosed a new risk, in the Accounting & Financial Operations category. Nevro Corp faces a significant financial risk due to...

Nevro Corp's Market Cap Challenges: Impairment Risks and Investor Concerns

Mizuho Securities analyst Anthony Petrone has maintained their neutral stance on NVRO stock, giving a Hold rating yesterday. Anthony Petrone's rati...

Hold Rating for Nevro Corp Amid Revenue Growth Challenges and Market Uncertainty

Engaged Capital adds BlackLine, exits Shake Shack, others in Q3

Nevro Corp ( ($NVRO) ) just unveiled an announcement. Nevro Corp. reported a better-than-expected worldwide revenue and adjusted EBITDA for Q3 2024...

Nevro Corp. Reports Strong Q3 2024 Financial Performance

Nevro (NVRO) announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1 SI Jo...

Nevro announces publication of new data on Nevro1 SI Joint Fusion System

PTLO

SHAK

Press Releases

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024

Contracts

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Nevro Reports Third-Quarter 2024 Financial Results

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

BrainsWay Ltd. - American Depositary Shares

BrainsWay

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Nevro

Nevro (NVRO) Opzioni

Nevro (NYSE:NVRO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO